RENAL-CELL CARCINOMA IN 2016: Advances in treatment — jostling for pole position

    loading  Checking for direct PDF access through Ovid


In 2016, two major trials provided conflicting evidence regarding the role of 1 year of adjuvant therapy with sunitinib for patients with high-risk renal-cell carcinoma. In the second-line metastatic setting, updated data from key trials showed that cabozantinib improved overall survival over everolimus, and nivolumab was associated with a better quality of life compared with everolimus. Finally, a phase II study in previously untreated patients showed cabozantinib to be superior to sunitinib.

Related Topics

    loading  Loading Related Articles